Barclays PLC Sells 1,366 Shares of Illumina, Inc. (NASDAQ:ILMN)

Barclays PLC cut its position in Illumina, Inc. (NASDAQ:ILMN) by 0.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 215,914 shares of the life sciences company’s stock after selling 1,366 shares during the quarter. Barclays PLC’s holdings in Illumina were worth $28,854,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ILMN. Golden State Wealth Management LLC acquired a new stake in shares of Illumina during the fourth quarter worth $32,000. Versant Capital Management Inc raised its stake in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Illumina in the 4th quarter worth about $45,000. Assetmark Inc. boosted its holdings in Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares during the period. Finally, Lee Danner & Bass Inc. acquired a new position in shares of Illumina during the 4th quarter worth approximately $48,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Trading Down 3.2 %

NASDAQ ILMN opened at $71.21 on Friday. The company has a market cap of $11.27 billion, a price-to-earnings ratio of -9.27, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The business’s fifty day moving average is $84.61 and its 200 day moving average is $120.40.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of several recent research reports. HSBC cut Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target for the company. in a research note on Friday, February 28th. Barclays cut their target price on Illumina from $100.00 to $77.00 and set an “underweight” rating for the company in a research report on Thursday, April 10th. TD Cowen cut Illumina from a “buy” rating to a “hold” rating and decreased their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Royal Bank of Canada cut their price objective on shares of Illumina from $128.00 to $112.00 and set an “outperform” rating for the company in a research report on Tuesday, April 8th. Finally, Piper Sandler increased their price objective on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Illumina currently has an average rating of “Moderate Buy” and an average target price of $138.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.